For & Against

What's Next

The next 3–6 months are an earnings-driven window. CNC has no large M&A or refinancing event teed up; what moves the stock is whether Medicaid HBR steps down from the Q4 2025 print of 93% and whether the +mid-30s Marketplace repricing for 2026 actually shows up in the loss ratio. Q1 and Q2 prints are the decisive readings — Q3 starts to color the 2027 setup once 2027 MA bids are priced.

No Results

The estimate sheet is where the disagreement is already visible. Over 90 days, FY26 EPS has been revised modestly up (consensus $3.02, vs $2.99 ninety days ago) while FY27 EPS has been revised down ($3.98, from $4.13). The market is pricing 2026 catch-up but is unwilling to extend the rebuild into 2027.

For / Against / My View

For

**1. Cheapest large managed-care name on every cut, against an intact cash engine.** EV/Sales of 0.09× is a 5–9× discount to UNH (0.83×) and ELV (0.48×); EV/EBITDA of 3.8× is roughly one-third of the Healthcare Plans median of 10.5×. The "GAAP loss" headline is misleading — $6.7B of the $7.6B FY25 operating loss was a non-cash goodwill writedown, while operating cash flow actually grew from $0.15B (FY24) to $5.09B (FY25) and FCF was $4.32B.

**2. The Marketplace MLR shock is annually re-pricable — and the reset is already filed.** Marketplace pricing is a hard reset every January. The same Centene book ran 71% HBR in Q1 2025 (priced for one risk pool) and 89–90% by Q2 2025 (the actual pool). Management has filed +mid-30s% rate increases across 95% of the 2026 book — the most aggressive repricing in the company's history. The 2025 ACA shock is a pricing problem with a pricing solution, and the solution is locked in for 1/1/2026.

**3. Balance sheet is in net cash, not stress.** Net debt swung from +$4.6B (FY24) to –$0.3B (FY25); cash and investments rose to $17.9B; the $4B revolver is undrawn; long-dated maturities (2034, 2054) carry no near-term refinancing wall. Days in claims payable held at 46 — reserves are not being raided. Altman Z 2.82, Piotroski F = 7/9 (actually higher than FY24).

Bull price target

$65

Timeline (months)

Primary catalyst: Q1 2026 earnings — first clean read on whether Medicaid HBR steps down from 93% and Marketplace HBR shows the rate-reset benefit. Methodology: $4.00 FY27 EPS × 16× = $64; round to $65.

Against

**1. Management credibility is in the rebuild phase, not the rebuilt phase.** Management reaffirmed FY25 adj EPS >$7.25 on the Q1 2025 call, then withdrew the guide three months later via 8-K and reset to ~$1.75 — a 71% one-year shortfall. The "high-89s" Medicaid HBR target, the 12–15% long-term EPS growth target, and the implicit MA-breakeven pledge were not formally retracted; they were quietly removed from the deck. Asking the equity to underwrite a >$3.00 FY26 guide from the same team, in the same quarter as a securities class action and a $6.7B goodwill writedown, ignores the freshest data point on this team's forecasting accuracy.

**2. The 2027 cliff is locked in while the 2026 bridge is fragile.** Bulls focus on 2026 rate-catch-up; the more important number is that consensus FY27 EPS has been revised *down* (-1.5%) over the same 90-day window in which FY26 has been revised up. The smartest signal in the estimate sheet says the snapback does not compound. The mechanism is structural: OBBBA work requirements arrive in 2027 and will raise the morbidity of remaining Medicaid Expansion members; enhanced APTC expiry already cut Marketplace from 5.5M to 3.5M heading into 2026, sicker pool by selection; and management has pre-warned that the 2027 MA advance notice is "more pressured than industry expectations."

**3. The economic engine cannot absorb a single-quarter trend re-acceleration.** 92 cents of every premium dollar is medical cost. Normalized operating margin is ~2.0–2.5% on a $175B premium base; a 100-bp HBR miss wipes out roughly half of normalized operating income. FY25 ran consolidated HBR at 91.9% (Medicaid 93%, Marketplace 90%); FY26 guide implies 91.3% — i.e., management is asking the equity to underwrite ~60 bps of improvement against a sector where Humana's same-strategy MA book went from 4–5% margin to 1.1% in three years and Molina's pure-play Medicaid op margin collapsed from ~5% to 1.7% in the 2025 cohort.

Bear downside target

$25

Timeline (months)

Primary trigger: Q1 or Q2 2026 Medicaid HBR prints above 93% accompanied by negative prior-period development. Methodology: FY26 adj EPS prints $2.00 (vs guide >$3.00) × 12.5× multiple = $25.

The Tensions

1. The $6.7B goodwill impairment — non-cash optics, or the market correctly re-rating WellCare?

Bull says strip out the writedown and the company actually generated $5.09B of operating cash flow in the loss year and swung to net cash; the loss was funded through the income statement, not the balance sheet. Bear says the same writedown was the market correctly re-pricing the WellCare deal, and the resulting "net cash" position came from gutting equity, not from real deleveraging — a free-pass interpretation. Both cite the same $6.7B impairment. This resolves on FY26 operating cash flow conversion: a repeat $4–5B OCF year validates the "non-cash" framing; a step-down toward $1–2B says the cash engine was carrying FY25 working-capital tailwinds that don't recur.

2. The FY26 guide of >$3.00 EPS — re-pricable book, or the same team that just missed by 71%?

Bull says Marketplace pricing is a hard January reset and the +mid-30s repricing across 95% of the book is locked in for 1/1/2026, so the FY26 EPS bridge is mechanically achievable. Bear says the same management team reaffirmed FY25 adj EPS >$7.25 on the Q1 2025 call and reset to $1.75 three months later — there is no reason to underwrite the >$3.00 number more confidently than the >$7.25 number. Both cite the FY26 guide. This resolves on Q1 and especially Q2 2026 Medicaid HBR: a step-down from 93% with positive prior-period development validates the rate cycle; flat or negative says the team is again front-running acuity.

3. Consensus FY27 EPS at $3.98 — drift back toward $4.10+, or the smartest signal in the sheet?

Bull's $65 price target rests on $4.00 FY27 EPS × 16× and frames the recent drift from $4.13 to $3.98 as a temporary dislocation that reverses once Marketplace repricing prints. Bear cites the same number and the same trajectory as proof that the snapback does not compound — FY26 estimates are drifting up while FY27 is drifting down, which is the market's quiet verdict that 2027 morbidity (OBBBA, EAPTC) overwhelms the 2026 rate cycle. Both cite the FY27 estimate trajectory. This resolves on the post-Q2 2026 revision tape: if FY27 estimates inflect up after the July print, the bull is right; if they continue drifting down even after a clean Q2, the bear is right.

My View

I'd lean cautious and pass at $42 — the Against side weighs more, and tension #2 is what tips it. The price-cycle math the bull is selling is real and mechanically sound, but management has just missed by 71% on a guide they reaffirmed three months earlier; underwriting a >$3.00 FY26 print from the same team with the same forecasting tools is the kind of bet you take after the team has proven the rebuild, not before. Tension #3 is the cleanest tiebreaker — the analyst community is already taking 2026 estimates up while marking 2027 down, and the bull case requires the opposite pattern to play out. The one thing that would flip me: a Q2 2026 Medicaid HBR print at or below 91% with positive prior-period development and a visible inflection up in FY27 consensus over the following month. If both happen, the rate cycle is real and compounding, and the $3.98 → $4.10+ drift the bull needs becomes the path of least resistance.